Natural Agents Modulating Ferroptosis in Cancer: Molecular Pathways and Therapeutic Perspectives.

Ferroptosis, a controlled cell death influenced by iron-dependent lipid peroxidation, presents potential therapeutic targets for cancer treatment due to its unique molecular pathways and potential drug resistance. Natural compounds, such as polyphenols, flavonoids, terpenoids and alkaloids, can influence ferroptosis via important signalling pathways, such as Nrf2/Keap1, p53, and GPX4. These are promising for combinational therapy due to their ability to cause ferroptotic death in cancer cells, exhibit tumour-specific selectivity and reduce systemic toxicity.

The Microbiota-Gut-Brain Connection: A New Horizon in Neurological and Neuropsychiatric Disorders.

Introduction: The microbiota-gut-brain axis (MGBA), a complex two-way connection between the gut microbiota and the brain, has become a key regulator of neurological and neuropsychiatric disorders. Neurological disorders and gut microbiota dysbiosis are linked to these diseases. Changes in gut microbiota can lead to neurotransmitter imbalances, oxidative stress, and neuroinflammation.

Biodegradable packaging film from watermelon rind pectin and pineapple peel nanocellulose: Preparation, characterization and food application.

This study developed pectin nanocellulose (PNC) composite films using pectin extracted from watermelon rind and nanocellulose (NC) derived from pineapple peel. Films were prepared by incorporating varying NC concentrations (2 %, 5 %, 7 %, and 10 %) into the pectin matrix and characterized for optical, barrier, mechanical, thermal, and biodegradation properties, as well as their effectiveness in extending the shelf life of fresh-cut cauliflower. Fourier Transform Infrared Spectroscopy (FTIR) confirmed NC integration into the pectin matrix.

Antibody-functionalized lipid nanocarriers for RNA-based cancer gene therapy: advances and challenges in targeted delivery.

Despite remarkable advances in cancer therapeutics, conventional treatments still face significant hurdles, including systemic toxicity, poor tumor specificity, multidrug resistance, and suboptimal intracellular delivery. Lipid-based nanocarriers (LBNCs) have emerged as versatile platforms for delivering therapeutic RNA molecules, offering biocompatibility and tunable properties that enhance drug stability and bioavailability. Functionalizing these nanocarriers with antibodies has unlocked new potential for achieving precise tumor targeting, leveraging the overexpression of specific receptors on cancer cells.